SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukaemia. Blood. 1975; 46: 219234.
  • 2
    Binet JL, Leporrier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukaemia. Cancer. 1977; 40: 855864.
  • 3
    Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukaemia. Blood. 1989; 74: 1925.
  • 4
    Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukaemia. J Clin Oncol. 1991; 9: 4449.
  • 5
    Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet. 1996; 347: 14321438.
  • 6
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med. 2000; 343: 17501757.
  • 7
    Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated Stage B and C chronic lymphocytic leukemia patients. Blood. 2001; 98: 23192325.
  • 8
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90: 21882195.
  • 9
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood. 1998; 92: 19271932.
  • 10
    Davis TA, White CA, Grillo-Lopez AJ, et al. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J Clin Oncol. 1999; 17: 18511857.
  • 11
    O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 21652170.
  • 12
    Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001; 19: 21532164.
  • 13
    Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitisation to cytotoxic drugs. Cancer Res. 2001; 61: 51375144.
  • 14
    Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001; 114: 800809.
  • 15
    Schulz H, Klein SK, Rehwald U, et al. Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002; 100: 31153120.
  • 16
    Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 614.
  • 17
    Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94: 18401847.
  • 18
    Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 18481854.
  • 19
    Hamblin TJ, Orchard JA, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood. 2000; 95: 24552557.
  • 20
    Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001; 98: 26332639.
  • 21
    Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of disease. Blood. 2002; 99: 10231029.
  • 22
    Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002; 100: 46094614.
  • 23
    Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 17641775.
  • 24
    Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003; 101: 49444951.
  • 25
    Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 and prognosis in chronic lymphocytic leukaemia. Lancet. 2004; 363: 105111.
  • 26
    Rawstron AC, Kennedy B, Evans PAS, et al. Quantitation of minimal disease levels in chronic lymphocytic leukaemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001; 98: 2935.
  • 27
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute sponsored Working Group Guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 29: 49904997.
  • 28
    Mc Laughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 28252833.
  • 29
    Fleming TR. One-sample multiple testing procedure for Phase II clinical trials. Biometrics. 1982; 38: 143151.
  • 30
    Norman GR, Streiner DL. Biostatistics: the bare essentials. Hamilton, Ontario, Canada: BC Dekker Inc., 1997.
  • 31
    Del Principe MI, Del Poeta G, Venditti A, et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica. 2004; 89: 14681475.
  • 32
    Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood. 1997; 89: 20482059.
  • 33
    Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102: 15151525.
  • 34
    Gurrieri C, McGuire P, Zan H, et al. Chronic lymphocytic leukemia B cells undergo somatic hypermutation and intraclonal VHDJH gene diversification. J Exp Med. 2002; 196: 629639.
  • 35
    Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an update retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005; 105: 4953.
  • 36
    Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001; 19: 36113621.
  • 37
    Byrd JC, Houdle-McGrail LL, Hospenthal DR, Howard RS, Dow N, Diehl LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol. 1999; 105: 445447.
  • 38
    Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anemia with rituximab. Lancet. 2001; 358: 15111513.
  • 39
    Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998; 77: 8991.
  • 40
    Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999; 27: 791795.
  • 41
    Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998; 91: 33793389.
  • 42
    Byrd JC, Kitada S, Flinn IW, Pearson M, Shinn C, Reed J. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002; 99: 10381043.
  • 43
    Cheson BD, Zwiebel J. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998; 25: 4259.
  • 44
    Keating M, Lerner S, Kantarjian H, Freirech E, O'Brien S. The serum B2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood. 1995; 86: 606a.
  • 45
    Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004; 103: 12021210.
  • 46
    Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide, and rituximab achieve a high complete remission rate as initial treatment for chronic lymphocytic leukemia [abstract]. Blood. 2001; 98: 771a.
  • 47
    Del Principe MI, Del Poeta G, Maurillo L, et al. Addition of rituximab to fludarabine improves progression free survival in untreated ZAP-70 negative chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2004; 104: 477a.